Health committee  Mr. Chair, provinces and territories have assured us that they have good plans in place and they have the health workforce required to scale up, so they indicate that they have no issues with throughput. We'll continue to monitor that as closely as possible with them.

Health committee  Mr. Chair, thank you very much. It is very much a team effort. We work closely with provinces and territories as well as with other federal departments to ensure that the rollout is as efficient as possible. By the end of the day today, we'll have nearly four million doses distributed across the country.

Health committee  Mr. Chair, thank you for the question. We've been working quite extensively over the last three-plus months on setting the conditions for effective rollout, which started in December. We continue to build this so that we have an effective increase in capacity and an increased ability to deliver and scale up from April onwards, when more vaccines become available, into the millions a week, as well as additional 8° vaccines as they get added.

Health committee  Mr. Chair, there is no shift in date. If I said that, it's by mistake. It's by September, and with the numbers that we're seeing with the approval of the AstraZeneca vaccine, you'll see even more vaccines arrive sooner, and so that date might be revisited at a future point in time.

Health committee  Mr. Chair, I think this is a question that is best answered by integrating the inputs from the different provinces, but what provinces are telling us is that they can scale up significantly. They see no major obstacles to scaling up with the projections that we issued them. I think that with the efforts over the last few weeks and the culminating point that is the rehearsal on March 9, it's not an end date, but it is a good, important, way point to come together and confirm that we have a good line of sight in our plans and that additional risks are identified.

Health committee  Mr. Chair, what I'm saying is that it depends on the provinces' ability to scale up. The number of 300,000 a day that was mentioned earlier makes perfect sense. It's part of the projections that we shared with provinces, and they intend to scale up different types of vaccination clinics to meet that goal.

Health committee  Mr. Chair, there are ongoing discussions with the Canadian Armed Forces and the Department of National Defence. In close coordination with Indigenous Services Canada, plans exist to support provinces that require it for some of their remote and indigenous communities. We're actually seeing that now in northern Manitoba as well as northern Ontario and it's appeared in Newfoundland and Labrador, and so it will likely continue as required.

Health committee  Mr. Chair, we are in close coordination with Indigenous Services Canada and, of course, with the provincial and territorial authorities as well. They are the colleagues that distribute vaccines. The input of the different jurisdictions is also factored in, or discussed at, numerous tables.

Health committee  Thank you, Mr. Chair. For the province of Ontario at the end of March—my apologies, I have to do some math in public—as of today, it has been 1.57 million Pfizer doses, and for Moderna, 703,000 up to now.... In addition, there is a newly approved table of data that is in circulation.

Health committee  Yes, of course. We previously announced that we will have 23 million doses from Pfizer and Moderna during the second quarter. In the third quarter, we will be receiving more than 55 million doses. That will give us a total of 84 million doses from those two manufacturers alone.

Health committee  That is what the numbers tell us. The quantities will be sufficient to vaccinate all Canadians before the end of September.

Health committee  Yes. While we've focused in the last few months, or up until now, on establishing distribution networks, we're really focusing on supporting provinces to administer and execute their immunization plans. It's very much their responsibility.

Health committee  Mr. Chair, I'll need 10 seconds to find my data.

Health committee  Mr. Chair, I think I'll have to get back to you in a few seconds, if I may.

Health committee  Mr. Chair, we're focusing on helping provinces identify the risks and the additional requirements they may have in order to help them immunize at scale. The AstraZeneca and other non-mRNA vaccines have less stringent, less demanding cold chain requirements. They can be stored in the pharmaceutical fridges that you would find in pharmacies.